Treatment of Angiotensin Peptide (1-7) for COVID-19

Kanuni Sultan Suleyman Training and Research Hospital

Status: Completed

Conditions: COVID-19

Treatments: Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma

Study type: Interventional

Funder types: Other

Identifiers

NCT04375124

KSSEAH--0059

Details and patient eligibility

About

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Full description

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• accepted to participate with an informed consent
• proven positive COVID-19

Exclusion criteria

• declined to participate
• genetic/chromosomal abnormalities
• any kind of history of previous adverse events with transfusion
• diagnosis of immune deficiency

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

9 participants in 2 patient groups

non-peptide group

No Intervention group

Description:

This group will receive routine treatment and care for COVID-19.

peptide group

Active Comparator group

Description:

This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.

Treatment:

Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma